Compare TTWO & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | ONC |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | Switzerland |
| Employees | 12909 | 12000 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9B | 40.6B |
| IPO Year | 1999 | 2015 |
| Metric | TTWO | ONC |
|---|---|---|
| Price | $195.05 | $354.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 28 | 27 |
| Target Price | $286.21 | ★ $437.57 |
| AVG Volume (30 Days) | ★ 2.2M | 307.2K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 93.67 | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $6,656,400,000.00 | $238,387,000.00 |
| Revenue This Year | $28.42 | $26.55 |
| Revenue Next Year | $8.52 | $14.91 |
| P/E Ratio | ★ N/A | $1,167.87 |
| Revenue Growth | 18.16 | ★ 22179.16 |
| 52 Week Low | $183.86 | $253.95 |
| 52 Week High | $265.94 | $388.66 |
| Indicator | TTWO | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 41.86 |
| Support Level | $188.14 | $335.44 |
| Resistance Level | $220.55 | $373.56 |
| Average True Range (ATR) | 5.36 | 10.10 |
| MACD | -0.85 | -2.07 |
| Stochastic Oscillator | 38.14 | 15.74 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.